Faculty profile

Donald Poirier

ResearcherMolecular MedicineUniversité Laval

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université Laval directory, so their courses may be missing. Find their university profile.

Donald Poirier

Researcher

Molecular Medicine

Health Sciences

Université Laval

Quebec City, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
21 publications in the last five years, latest in 2026.
Senior (last) author on 6 recent papers, a sign of leading a research group.
Principal investigator on 10 research grants (10 CIHR), most recently in 2026.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

112

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Stéroïde Traitement Xénogreffe Synthèse Chimique Cancer Du Sein Enzyme Estrogène Hormone

Latest papers

Systemic and local chronic inflammation and hormone disposition promote a tumor-permissive environment for breast cancer in older women.
Nature aging · 2026
Developing Potential Endocrine Therapy Controlling Estradiol and DHT by Targeting 17β-HSD7 Against ER+ Breast Cancer.
Cells · 2026
Aminosteroid RM-581 Induces G0/G1 Arrest and Endoplasmic Reticulum Stress-Mediated Apoptosis in Human Acute and Chronic Leukemia Cell Lines.
Cancers · 2026 · senior author

All 112 publications

Latest funding

Pharmaceutical and preclinical development of a synthetic protectin DX analog for acute and chronic-pain control
CIHR · 2026 · Nominated PI
$757,352
Mise au point d'inhibiteurs covalents sélectifs pour le traitement et le diagnostic de cancers qui expriment la 17beta-HSD1
CIHR · 2025 · Nominated PI
$642,600
Potentiel thérapeutique des protectines contre les infections grippales
CIHR · 2024 · Co-investigator
$100,000

All 15 grants and awards

112 publications.

Systemic and local chronic inflammation and hormone disposition promote a tumor-permissive environment for breast cancer in older women.

Carleton N, Chang AC, Lee S, Li R, Zou J, Brown DD, Hooda J, Chen J, Kumar R, Klei LR, Rigatti LH, Newsome J, John Mary DJS, Atkinson JM, West RE, Nolin TD, Oberly PJ, Huang Z, Poirier D, Diego EJ, Lucas PC, Tseng GC, Lotze MT, McAuliffe PF, Zervantonakis IK, Oesterreich S, Lee AV

Nature aging2026

DOI: 10.1038/s43587-026-01173-4 PMID: 42509302

Developing Potential Endocrine Therapy Controlling Estradiol and DHT by Targeting 17β-HSD7 Against ER+ Breast Cancer.

Wang R, Wang X, Su P, Roy J, Poirier D, Lin SX

Cells2026

DOI: 10.3390/cells15151345 PMID: 42587755

Aminosteroid RM-581 Induces G0/G1 Arrest and Endoplasmic Reticulum Stress-Mediated Apoptosis in Human Acute and Chronic Leukemia Cell Lines.

Fleury M, Roy J, Maltais R, Durocher F, Poirier D

Cancers2026Senior author

DOI: 10.3390/cancers18071078 PMID: 41976301

Evaluation of combining the PDX analogue AN-137B with oseltamivir in a mouse model of severe influenza A (H1N1) infection.

Abed Y, Rhéaume C, Carbonneau J, Fortin N, Maltais R, Marette A, Poirier D, Boivin G

Antiviral therapy2025

DOI: 10.1177/13596535251405300 PMID: 41361734

A New Synthetic Analogue of Protectin DX With Enhanced Therapeutic Potential Against Metabolic-Associated Steatotic Liver Disease.

Desmarais F, Maltais R, Sancéau JY, Marcotte B, Guèvremont G, Trottier J, Mitchell PL, Barbier O, Poirier D, Marette A

FASEB journal : official publication of the Federation of American Societies for Experimental Biology2025

DOI: 10.1096/fj.202502152rrrr PMID: 41139243

Metabolite profiling in human and mouse liver microsomes of the aminosteroid RM-581, a new orally active anticancer agent.

Poirier D, Jutras M, Maltais R, Roy J, Fleury M

Bioorganic chemistry2025First author

DOI: 10.1016/j.bioorg.2025.108979 PMID: 40957191

Development of a Multigram Synthetic Route to RM-581, an Orally Active Aminosteroid Derivative Against Several Types of Cancers.

Maltais R, de Sainte Maresville D, Desrosiers V, Poirier D

Molecules (Basel, Switzerland)2025Senior author

DOI: 10.3390/molecules30112441 PMID: 40509328

Recent advances in the development of 17beta-hydroxysteroid dehydrogenase inhibitors.

Poirier D

Steroids2025First author

DOI: 10.1016/j.steroids.2024.109529 PMID: 39532224

Novel Copper(II) Coordination Compounds Containing Pyridine Derivatives of N4-Methoxyphenyl-Thiosemicarbazones with Selective Anticancer Activity.

Rusnac R, Garbuz O, Kravtsov V, Melnic E, Istrati D, Tsapkov V, Poirier D, Gulea A

Molecules (Basel, Switzerland)2024

DOI: 10.3390/molecules29246002 PMID: 39770091

Synthesis and characterization of targeted 17β-hydroxysteroid dehydrogenase type 7 inhibitors.

Sancéau JY, Maltais R, Zhou M, Lin SX, Poirier D

The Journal of steroid biochemistry and molecular biology2024Senior author

DOI: 10.1016/j.jsbmb.2024.106544 PMID: 38754521

Something wrong or missing on this profile? Suggest a correction

Donald Poirier

Research

Latest papers

Latest funding

Systemic and local chronic inflammation and hormone disposition promote a tumor-permissive environment for breast cancer in older women.

Developing Potential Endocrine Therapy Controlling Estradiol and DHT by Targeting 17β-HSD7 Against ER+ Breast Cancer.

Aminosteroid RM-581 Induces G0/G1 Arrest and Endoplasmic Reticulum Stress-Mediated Apoptosis in Human Acute and Chronic Leukemia Cell Lines.

Evaluation of combining the PDX analogue AN-137B with oseltamivir in a mouse model of severe influenza A (H1N1) infection.

A New Synthetic Analogue of Protectin DX With Enhanced Therapeutic Potential Against Metabolic-Associated Steatotic Liver Disease.

Metabolite profiling in human and mouse liver microsomes of the aminosteroid RM-581, a new orally active anticancer agent.

Development of a Multigram Synthetic Route to RM-581, an Orally Active Aminosteroid Derivative Against Several Types of Cancers.

Recent advances in the development of 17beta-hydroxysteroid dehydrogenase inhibitors.

Novel Copper(II) Coordination Compounds Containing Pyridine Derivatives of N4-Methoxyphenyl-Thiosemicarbazones with Selective Anticancer Activity.

Synthesis and characterization of targeted 17β-hydroxysteroid dehydrogenase type 7 inhibitors.

Pharmaceutical and preclinical development of a synthetic protectin DX analog for acute and chronic-pain control

Mise au point d'inhibiteurs covalents sélectifs pour le traitement et le diagnostic de cancers qui expriment la 17beta-HSD1

Potentiel thérapeutique des protectines contre les infections grippales

Pre-clinical pharmacokinetic and efficacy assays with an efficient 17beta-hydroxysteroid dehydrogenase type 7 inhibitor for breast cancer therapy

Aminosteroid derivatives as a new class of cholesterol homeostasis disruptors for selective treatment of pancreatic cancer: Mechanistic and translational studies

3alpha-hydroxysteroid dehydrogenase type 3 as a modulator of human adipose tissue function and distribution

Démonstration de l'efficacité du premier inhibiteur irréversible et sélectif de la 17beta-HSD1 pour le traitement des cancers du sein sensibles aux estrogènes

Développement d'un traitement sélectif de l'endométriose : Étude du potentiel du premier inhibiteur irréversible de la 17beta-HSD1 chez le primate

Évaluation d'une nouvelle famille d'aggravateurs du stress du réticulum endoplasmique pour traiter le cancer du pancréas

Optimisation du potentiel thérapeutique de dérivés aminostéroïdes contre le cancer de l'ovaire

Frequent collaborators

Sheng-Xiang Lin

Francine Durocher

Guy Boivin

Olivier Barbier

Anie Philip

Daniel Lamarre

Caroline Diorio

Laurent Chatel-Chaix

Julie Fradette

Sachiko Sato

Jean-Philippe Lambert

Vincent Giguere

Nicolas Bertrand

Hassan Fahmi

Donald Poirier

Research

Latest papers

Latest funding

Systemic and local chronic inflammation and hormone disposition promote a tumor-permissive environment for breast cancer in older women.

Developing Potential Endocrine Therapy Controlling Estradiol and DHT by Targeting 17&#x3b2;-HSD7 Against ER+ Breast Cancer.

Aminosteroid RM-581 Induces G0/G1 Arrest and Endoplasmic Reticulum Stress-Mediated Apoptosis in Human Acute and Chronic Leukemia Cell Lines.

Evaluation of combining the PDX analogue AN-137B with oseltamivir in a mouse model of severe influenza A (H1N1) infection.

A New Synthetic Analogue of Protectin DX With Enhanced Therapeutic Potential Against Metabolic-Associated Steatotic Liver Disease.

Metabolite profiling in human and mouse liver microsomes of the aminosteroid RM-581, a new orally active anticancer agent.

Development of a Multigram Synthetic Route to RM-581, an Orally Active Aminosteroid Derivative Against Several Types of Cancers.

Recent advances in the development of 17beta-hydroxysteroid dehydrogenase inhibitors.

Novel Copper(II) Coordination Compounds Containing Pyridine Derivatives of N4-Methoxyphenyl-Thiosemicarbazones with Selective Anticancer Activity.

Synthesis and characterization of targeted 17&#x3b2;-hydroxysteroid dehydrogenase type 7 inhibitors.

Frequent collaborators

Sheng-Xiang Lin

Francine Durocher

Guy Boivin

Olivier Barbier

Anie Philip

Daniel Lamarre

Caroline Diorio

Laurent Chatel-Chaix

Julie Fradette

Sachiko Sato

Jean-Philippe Lambert

Vincent Giguere

Nicolas Bertrand

Hassan Fahmi

Developing Potential Endocrine Therapy Controlling Estradiol and DHT by Targeting 17β-HSD7 Against ER+ Breast Cancer.

Synthesis and characterization of targeted 17β-hydroxysteroid dehydrogenase type 7 inhibitors.